AMRO Flags Rising Philippine Stagflation Risk as Stronger Inflation Pass-Through Threatens Consumption

Why It Matters

Stagflation threatens consumer‑driven growth and could pressure investors, while the health‑care tax relief offers a narrow counterbalance but faces structural constraints.

Key Takeaways

• AMRO cuts 2026 Philippines GDP forecast to 4.1%, down from 5.3%.
• Expected 2026 inflation rises to 6%, breaching BSP's 4% ceiling.
• Higher inflation pass‑through threatens household consumption, risking stagflation.
• Government expands VAT exemption to 2,263 essential medicines to curb costs.
• Generic drug makers face growth risk from import reliance and limited R&D.

Pulse Analysis

The latest AMRO interim update paints a sobering picture for the Philippines, where growth is projected to dip to a post‑pandemic low of 4.1% in 2026. The agency attributes this slowdown to a sharper inflation pass‑through, with headline rates expected to average 6%—well above the Bangko Sentral ng Pilipinas' 4% comfort zone. Elevated food and energy prices are squeezing disposable incomes, curbing the consumption‑driven engine that has powered the country’s recent expansion. For investors and policymakers, the looming stagflation scenario raises concerns about debt sustainability and the effectiveness of monetary policy in a highly import‑dependent economy.

To mitigate the cost‑of‑living pressure, Manila has broadened VAT exemptions on essential medicines, now covering 2,263 items ranging from cancer treatments to diabetes drugs. The move aims to lower out‑of‑pocket health expenses, which accounted for 42.7% of total health spending in 2025, and to stimulate demand for locally produced generics. This policy aligns with the Philippine Development Plan’s goal of boosting domestic manufacturing capacity by 40% by 2028, and it dovetails with incentives such as dedicated pharmaceutical parks and a proposed corporate tax cut from 25% to 20% to attract foreign investment.

Despite these incentives, the pharmaceutical sector faces structural headwinds. Heavy reliance on imported active ingredients and a thin domestic R&D pipeline limit long‑term competitiveness. Skilled‑labor shortages further constrain scaling efforts. If the government can pair tax relief with measures to develop local supply chains and research capabilities, the sector could become a growth engine that offsets broader macroeconomic weakness. Otherwise, the combination of high inflation and constrained domestic demand may deepen stagflation risks, prompting investors to reassess exposure to Philippine consumer‑sensitive assets.